Daiichi Sankyo and Astellas buy back more shares
This article was originally published in Scrip
Executive Summary
Daiichi Sankyohas completed the acquisition of a further 15 million of its own shares, around 2% of the outstanding total, for ¥45.7 billion ($425.1 million). In a similar move to improve shareholder returns and guard against possible hostile takeovers, Astellas's board has just approved a similar buy back of up to 10 million of the firm's shares (again around 2% of the total) this month for a maximum of ¥50 billion.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.